TP53 and myelodysplastic syndrome: Survival analysis among these patients showed that those with MDS/AML with mutated TP53 (4.0 months for LFS, 4.1 months for OS) and with MDS-related cytogenetic abnormalities (10.6 months for LFS and OS) had the worst outcomes (MDS/AML with mutated TP53 vs. MDS/AML with MDS-related cytogenetic abnormalities, P = 0.399 for LFS, P = 0.131 for OS), followed by those with MDS-related gene mutations (vs. MDS/AML with mutated TP53; 10.7 months for LFS, P = 0.004; 20.7 months for OS, P < 0.001).